Table 2.

Percentage of vaccine doses followed by a solicited local symptom during the 7-day postvaccination period^a

Symptom and grade	HepB+HPV group				HepB group (n = 226)b
	HepB (n = 228)b		HPV-16/18 (n = 227)b
	No. of doses	% of doses (95% CI)	No. of doses	% of doses (95% CI)	No. of doses	% of doses (95% CI)
Pain
All	123	53.9 (47.2–60.5)	202	89.0 (84.2–92.7)	132	58.4 (51.7–64.9)
Grade 3	1	0.4 (0.0–2.4)	7	3.1 (1.2–6.3)	2	0.9 (0.1–3.2)
Redness
All	23	10.1 (6.5–14.8)	44	19.4 (14.5–25.1)	20	8.8 (5.5–13.3)
Grade 3	0	0.0 (0.0–1.6)	0	0.0 (0.0–1.6)	0	0.0 (0.0–1.6)
Swelling
All	14	6.1 (3.4–10.1)	43	18.9 (14.1–24.7)	14	6.2 (3.4–10.2)
Grade 3	1	0.4 (0.0–2.4)	2	0.9 (0.1–3.1)	1	0.4 (0.0–2.4)

^aIncludes the first three doses of HepB vaccine and all three doses of HPV-16/18 vaccine; TVC active phase.

^bn, total number of doses.